Vital Therapies, Inc. (NASDAQ:VTL) has posted results for the last fiscal year, recording EPS of $-1.38. For this year, EPS is anticipated to grow 36.90% over the preceding year, while next year’s EPS is predicted to increase 18.60%.
The Barchart Technical Opinion rating is a 16% Sell with a Weakening short term outlook on maintaining the current direction. Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.
Recently, Vital Therapies, Inc. (NASDAQ:VTL) reported that for the previous five years, EPS at Vital Therapies, Inc. has increased -33.80%. The combined EPS growth for the imminent five years is projected to be 15.50%.
Shares of Vital Therapies, Inc. are now trading at $3.30, giving it market cap of $139.26M. Over the last 12 months, shares of Vital Therapies, Inc. have risen to maximum of $-60.55% and declined to a minimum of $46.67%.
Vital Therapies, Inc. shows 20-Day Simple Moving Average of $8.91% and 50-Day Simple Moving Average of $-6.01%. The 200-Day SMA is $-31.66%.
The stock’s weekly performance is 20.00% while its monthly performance is -13.16%. Year-to-date the equity has moved -24.14% compared to a performance of -56.75% over the preceding 12 months.
Vital Therapies, Inc. has witnessed 40.59% insider transactions, showing insider ownership of 30.78%. That compares to 27.20% ownership by institutional investors after 29.05% institutional transactions.
Vital Therapies, Inc. has RSI (Relative Strength Index) of 53.83.
Vital Therapies, Inc. (NASDAQ:VTL), a biotherapeutic company developing ELAD(R), a cell-based therapy targeting the treatment of acute forms of liver failure, announced results for the first quarter ended March 31, 2017.